Navigation Links
Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
Date:10/7/2008

ater this year. In addition, RDEA119 is being evaluated in a Phase 1 trial in patients with advanced cancer, and will be also be evaluated in a Phase 1/2 clinical trial in the fourth quarter of 2008 in combination with Nexavar(R) (sorafenib) in advanced cancer patients. The Company also plans to initiate a Phase 1 trial of RDEA436, its second-generation MEK inhibitor, in healthy volunteers, in the fourth quarter of this year.

About RDEA119 and RDEA436

RDEA119 and RDEA436, non-ATP competitive, highly-selective MEK inhibitors for the treatment of cancer and inflammatory diseases, are two of the compounds from Ardea's MEK inhibitor research and development program. RDEA119 has shown potential as a potent and selective inhibitor of MEK, which is believed to play an important role in cancer cell proliferation, apoptosis and metastasis. Preclinical and clinical results suggest that RDEA119 has favorable properties, including oral dosing, excellent selectivity and limited retention in the brain, which, in turn, may result in a reduced risk of central nervous system (CNS) side effects. Preclinical data show that RDEA436 is a potent in-vitro and in-vivo inhibitor of MEK, has favorable pharmacokinetic properties with low CNS penetration and a long half-life in a human micro-dose study indicating the potential for once daily dosing in humans.

About Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, gout, cancer and inflammatory diseases. We have five product candidates in clinical trials and others in preclinical development and discovery. Our most advanced product candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation NNRTI for the treatment of HIV,
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
2. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
3. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
4. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
5. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
6. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
7. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
10. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
11. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Sept. 15, 2014  Dr. Navneet Sharda M.D . ... recently announced their continued investment in cutting edge cancer treatments ... at the Center and a national reputation as leaders in ... speaking with multiple cancer survivors who have undergone cancer treatment ... both his warm, friendly manner and his belief in the ...
(Date:9/15/2014)... 15, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... stringent listing criteria for the NASDAQ Global Select Market ... exchange from the NYSE MKT. The company will continue ... NASDAQ Global Select Market, a segment of ... standards of any exchange in the world, requiring that ...
(Date:9/15/2014)... 2014  The Female Health Company (NASDAQ-CM: FHCO) today ... Company,s management team as Executive Vice President of Global ... that Michael Pope will retire from his ... September 15, 2014.  Following his retirement, Mr. Pope will ... Prior to joining The Female Health Company ...
Breaking Medicine Technology:Cancer Care Center Emphasizing Innovative Oncology Treatments 2Inovio Pharmaceuticals (INO) Begins Trading on NASDAQ Global Select Market Exchange 2Inovio Pharmaceuticals (INO) Begins Trading on NASDAQ Global Select Market Exchange 3The Female Health Company Appoints Martin Tayler Executive Vice President of Global Operations 2The Female Health Company Appoints Martin Tayler Executive Vice President of Global Operations 3
... May 9, 2011 Optimer Pharmaceuticals, Inc. (NASDAQ: ... abstracts at the 2011 Digestive Disease Week (DDW) conference ... of DIFICID™ (fidaxomicin), an investigational product for the treatment ... (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) The first analysis ...
... Australia and BEIJING, May 9, 2011 Saladax Biomedical, ... diagnostic assays to achieve the promise of personalized medicine ... of its Pacific Rim commercialization team to expand its ... Saladax,s Pacific Rim commercialization team include: ...
Cached Medicine Technology:Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 2Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 3Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 4Saladax Biomedical, Inc. Announces Pacific Rim Commercialization Team in Australia and China 2
(Date:9/15/2014)... September 15, 2014 The Best ... World Report consists of seven hospitals using OnBase as ... Hospital and Cleveland Clinic were ranked at the top ... respectively. The rankings cover nearly 5,000 medical centers across ... 17 hospitals that scored highest in at least six ...
(Date:9/15/2014)... 2014 (HealthDay News) -- U.S. heart experts recommend doctors ... when evaluating young people for underlying heart disease that ... Heart Association and the American College of Cardiology said ... and family medical history along with a physical examination ... (existing from birth) risks for sudden cardiac death. ...
(Date:9/15/2014)... estimated 8% of Americans will suffer from post traumatic ... Brought on by an overwhelming or stressful event or ... physiology of the brain. Understanding how threat is processed ... is essential to developing effective interventions. , New ... of Texas at Dallas published online today in ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 This year, ... its founding in 2007. To mark the special occasion, ... for supporting the village and helping it to get ... safe, secure and fun community for seniors. Members of ... community and live in their own homes. They are ...
(Date:9/15/2014)... HealthDay Reporter MONDAY, Sept. 15, 2014 ... responsible for sending thousands of young children to the hospital ... year between 2007 and 2011, about 9,500 U.S. children younger ... family members, medication, according to the U.S. Centers for Disease ... just 1 or 2 years old," said Dr. Daniel Budnitz, ...
Breaking Medicine News(10 mins):Health News:Seven of Top Ten Hospitals in the U.S. Leverage OnBase by Hyland ECM Solution 2Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 2Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 3Health News:EEG study findings reveal how fear is processed in the brain 2Health News:Avenidas Village Celebrates Anniversary 2Health News:Small Number of Drugs Behind Kids' Accidental Poisonings: CDC 2Health News:Small Number of Drugs Behind Kids' Accidental Poisonings: CDC 3
... Axel Ullrich, Ph.D., is the recipient of the ... his pioneering work in the translation of genomics-based discoveries ... Director of Molecular Biology at the Max Planck Institute ... expert in gene technology and one of the most ...
... of activity helped men, women regardless of family history ... level of aerobic fitness can significantly reduce stroke risk ... study. , The study, expected to be presented Thursday ... New Orleans, showed 30 minutes or more of brisk ...
... connection, experts say , , THURSDAY, Feb. 21 (HealthDay News) ... anywhere else for that matter, may raise your risk ... , "These authors report a potentially important association between ... said Dr. Steven V. Pacia, director of neurology at ...
... similarities, differences in DNA, studies find , , THURSDAY, ... such examination of human genetic diversity yet conducted, an ... to track differences and similarities between people around the ... Science , a team led by Richard Myers, ...
... drugs raises risk of adverse side effects ... take more than one nonsteroidal anti-inflammatory drug (NSAID) may ... suggests. , NSAIDs, which are available in both prescription ... arthritis. , These drugs are widely available, and patients ...
... release is available in Spanish . , ... field of health. However, they are vitally important for patients ... carried out at the Department of Social Anthropology ... lecturer Rafael Briones Gmez, shows that Spanish hospitals are not ...
Cached Medicine News:Health News:Pezcoller Foundation-AACR International Award for Cancer Research recognizes Axel Ullrich 2Health News:Pezcoller Foundation-AACR International Award for Cancer Research recognizes Axel Ullrich 3Health News:Moderate Aerobic Fitness Levels May Cut Stroke Risk 2Health News:Daytime Dozing Might Raise Stroke Risk 2Health News:Global Analysis of Human DNA Tracks Migration, Identity 2Health News:Global Analysis of Human DNA Tracks Migration, Identity 3Health News:Global Analysis of Human DNA Tracks Migration, Identity 4Health News:Taking Multiple Pain Relievers May Cause Complications 2Health News:Patients' relatives are ignored by the health system and suffer emotional stress 2
... SF (slot format) microfiltration units provide a ... acid in solution onto nitrocellulose or Zeta-Probe ... by using interchangeable templates to form the ... Bio-Dot SF apparatus. Each is available as ...
Dot Blotter - 96-Well Dot Blot...
... base with vacuum stage, porous vacuum plate, reservoir ... instructions. The Model 785 vacuum blotter quickly ... agarose gel onto a nylon membrane. Because it ... nucleic acid samples can be separated on a ...
Mini Trans-Blot and PowerPac 300 System, 110-120 V...
Medicine Products: